XML 78 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment and Geographic Information
12 Months Ended
Jun. 27, 2015
Segments and Geographic Information [Abstract]  
Segment and Geographic Information
SEGMENT AND GEOGRAPHIC INFORMATION
    
As discussed in Note 1, in conjunction with the Omega acquisition, we changed our reporting segments to better align with our new organizational structure. This structure is consistent with the way our chief operating decision maker makes operating decisions, allocates resources and manages the growth and profitability of the business. Operating segments with similar economic characteristics, including long-term profitability, nature of the products sold and production processes, distribution methods, and classes of customers, are aggregated as reportable segments.

We generated third-party net sales in the following geographic locations(1) during each of the fiscal years presented (in millions):
 
2015
 
2014
 
2013
Ireland
$
344.0

 
$
146.7

 
$

U.S.
3,303.6

 
3,291.6

 
2,978.1

Europe
613.6

 
217.2

 
164.0

All other countries (2)
342.7

 
405.3

 
397.7

 
$
4,603.9

 
$
4,060.8

 
$
3,539.8


(1)    We attribute net sales to countries based on sales location.
(2)    Includes sales generated primarily in Israel, Mexico, Australia, and Canada.

The net book value of property and equipment at June 27, 2015 and June 28, 2014 was as follows (in millions):
 
June 27,
2015
 
June 28,
2014
Ireland
$
1.4

 
$
2.0

U.S.
558.6

 
530.7

Europe
153.8

 
31.7

Israel
119.8

 
119.6

All other countries
98.8

 
95.9

 
$
932.4

 
$
779.9



Sales to Walmart accounted for 15% of consolidated net sales in fiscal year 2015 and 19% in both fiscal year 2014 and fiscal year 2013. Sales to Walmart are reported primarily in our CHC segment.

Below is a summary of our results by reporting segment for fiscal years 2015, 2014, and 2013. Prior periods have been restated to conform to our new reporting segments (in millions).
 
CHC
 
BCH (1)
 
Rx Pharmaceut-icals
 
Specialty Sciences (2)
 
Other
 
Unallocated expenses
 
Total (3)
Fiscal Year 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,750.0

 
$
401.1

 
$
1,001.1

 
$
344.0

 
$
107.7

 
$

 
$
4,603.9

Operating income (loss)
$
405.6

 
$
26.6

 
$
373.9

 
$
36.3

 
$
26.8

 
$
(121.5
)
 
$
747.7

Operating income %
14.7
%
 
6.6
%
 
37.3
%
 
10.6
 %
 
24.9
%
 
%
 
16.2
%
Total assets
$
4,381.6

 
$
6,441.1

 
$
2,667.9

 
$
5,979.0

 
$
251.0

 
$

 
$
19,720.6

Capital expenditures
$
80.5

 
$
3.6

 
$
42.9

 
$
0.5

 
$
6.4

 
$
3.1

 
$
137.0

Property and equip, net
$
600.0

 
$
122.5

 
$
124.1

 
$

 
$
85.8

 
$

 
$
932.4

Depreciation/amortization
$
123.2

 
$
38.3

 
$
85.1

 
$
291.6

 
$
10.6

 
$

 
$
548.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,849.4

 
$

 
$
927.1

 
$
146.7

 
$
137.6

 
$

 
$
4,060.8

Operating income (loss)
$
413.1

 
$

 
$
349.8

 
$
(68.6
)
 
$
46.1

 
$
(173.4
)
 
$
567.0

Operating income (loss) %
14.5
%
 
%
 
37.7
%
 
(46.7
)%
 
33.5
%
 
%
 
14.0
%
Total assets
$
4,931.0

 
$

 
$
2,537.2

 
$
6,096.6

 
$
288.0

 
$

 
$
13,852.8

Capital expenditures
$
128.3

 
$

 
$
32.9

 
$

 
$
10.4

 
$

 
$
171.6

Property and equip, net
$
577.3

 
$

 
$
104.8

 
$
2.1

 
$
95.7

 
$

 
$
779.9

Depreciation/amortization
$
106.6

 
$

 
$
86.5

 
154.4

 
$
11.4

 
$

 
$
358.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year 2013
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,671.0

 
$

 
$
709.5

 

 
$
159.3

 
$

 
$
3,539.8

Operating income (loss)
$
401.8

 
$

 
$
263.2

 

 
$
48.9

 
$
(34.7
)
 
$
679.1

Operating income %
15.0
%
 
%
 
37.1
%
 
 %
 
30.7
%
 
%
 
19.2
%
Total assets
$
3,447.5

 
$

 
$
1,604.9

 

 
$
284.5

 
$

 
$
5,336.9

Capital expenditures
$
97.1

 
$

 
$
17.7

 

 
$
17.3

 
$

 
$
132.2

Property and equip, net
$
508.0

 
$

 
$
80.8

 

 
$
92.7

 
$

 
$
681.4

Depreciation/amortization
$
96.1

 
$

 
$
54.9

 

 
$
9.1

 
$

 
$
160.2



(1)    BCH only includes activity from March 30, 2015 to June 27, 2015.
(2)    Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014 for fiscal year 2014.
(3)     Amounts may not cross-foot due to rounding.

The following is a summary of our net sales by category by fiscal year (in millions):

2015
 
2014
 
2013
CHC

 

 

Cough/Cold/Allergy/Sinus (1)
$
486.2

 
$
510.1

 
$
500.6

Analgesics (1)
441.7

 
504.0

 
536.0

Gastrointestinal (1)
395.3

 
400.1

 
388.8

Infant nutritionals
383.9

 
374.8

 
350.1

Smoking cessation
299.4

 
236.8

 
193.2

Vitamins, minerals and dietary supplements
185.6

 
176.9

 
158.3

Animal health
156.9

 
178.0

 
123.2

Other CHC (1), (2)
335.9

 
468.7

 
420.9

Total CHC
2,684.9

 
2,849.4

 
2,671.1

BCH branded OTC products
401.2

 

 

Generic prescription drugs
1,066.1

 
927.1

 
709.5

Tysabri® royalties
344.0

 
146.7

 

Active pharmaceutical ingredients
107.7

 
137.6

 
159.3

Total net sales
$
4,603.9

 
$
4,060.8

 
$
3,539.8


(1)    Includes sales from our OTC contract manufacturing business.
(2) 
Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets none of which is greater than 10% of the CHC segment.